← Statins × lipids

SynthesisCurrent diabetes reports2025

Statins and Type 1 Diabetes: Impact on Cardiovascular Outcomes and surrogates. Systematic Review and meta-analysis.

Karen Feriz-Bonelo et al.PubMed ↗Publisher ↗

  • Statin uselooks good hereLower LDL cholesterol, lower major heart events.Correlation only, not a test of it.

What the trial testedas reported · 2025

Not counted

Probably lowered LDL cholesterol

−30.3mg/dL−47.0 to −13.6

statin use vs no statin use

As reported

difference −30.3 mg/dL, 95% CI −47.0 to −13.6 · the paper's word: low-density lipoprotein cholesterol (LDL-C)

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Statin use went with lower major heart events

−23%−30% to −16%

statin use vs no statin use

Bigger than 5 in 10 for cardiovascular events

As reported

HR 0.77, 95% CI 0.70–0.84 · the paper's word: major adverse cardiovascular events (MACE)

Who was studied, and how

people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

statin use
no statin use

Probably lowered LDL cholesterol−30.3

randomised

Already taking statin use, or nottheir own situation, not assigned

on statin use
not on statin use

Statin use went with lower major heart events−23%

correlation, not a test

the abstract, start to end

… with a pooled hazard ratio (HR) of 0.77 (95% CI: 0.70-0.84; low certainty), and a mean low-density lipoprotein cholesterol (LDL-C) reduction of 30.3 mg/dL (95% CI: -47.02 to …

← favours treatmentfavours comparator →
could be chance
Major adverse cardiovascular events (MACE)statin use vs no statin use
HR 0.770.70–0.84
Low-density lipoprotein cholesterol (LDL-C)statin use vs no statin use
−30.3−47.0 to −13.6
StatinsLipidsCardiovascular events
1 / 4

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 41082048